Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Papaverine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 1.00 |
| ▸ | PDE3A known ✓ | Q14432 | 10/20 | 0.97 |
| ▸ | PDE3B known ✓ | Q13370 | 9/20 | 0.97 |
| ▸ | PDE4D known ✓ | Q08499 | 2/20 | 0.97 |
| ▸ | PDE4A known ✓ | P27815 | 2/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.97 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.97 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.97 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.97 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.71 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.71 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.71 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.71 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.71 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.61 |
| ▸ | PDE10A | Q9Y233 | 13/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Papaverine SCHEMBL5500363 | 1.00 | PDE10A (1.00) | PDE10ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Papaverine SCHEMBL9614479 | 1.00 | PDE10A (1.00) | PDE10ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Papaverine SCHEMBL121268 | 1.00 | PDE10A (1.00) | PDE10ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Papaverine SCHEMBL29696479 | 1.00 | PDE10A (1.00) | PDE10ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Papaverine SCHEMBL11139932 | 0.99 | PDE10A (0.97) | PDE10ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Papaverine SCHEMBL29360983 | 0.99 | PDE10A (1.00) | PDE10ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Papaverine SCHEMBL34702 | 0.99 | PDE10A (1.00) | PDE10ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Papaverine SCHEMBL9551009 | 0.99 | PDE10A (1.00) | PDE10ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Papaverine SCHEMBL29387160 | 0.99 | PDE10A (1.00) | PDE10ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Papaverine SCHEMBL677440 | 0.97 | PDE10A (0.97) | PDE10ASMN1; SMN2CYP3A4MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121499821-B | Application of product of targeting Vasorin protein in preparation of products for diagnosing or treating sugar tolerance-reduced nephropathy | 天津医科大学朱宪彝纪念医院(天津医科大学代谢病医院、天津代谢病防治中心) | 2026-05-15 | — | — | CN | claimed |
| WO-2025235969-A2 | METHODS OF TREATMENT USING BIOMARKER-GUIDED PLASMAPHERESIS | CIRCULATE HEALTH, INC. (US) | 2025-11-13 | — | — | WO | claimed |
| CN-119971004-A | Application of Vasorin in preparation of anti-ischemic cardiomyopathy and anti-fibrosis drugs | 中国人民解放军空军军医大学 | 2025-05-13 | — | — | CN | claimed |
| WO-2024153636-A1 | VASORIN AS A BIOMARKER AND BIOTARGET IN NEPHROLOGY | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-07-25 | — | — | WO | claimed |
| WO-2024036387-A1 | CONCENTRATE OF PROTEINS AND PEPTIDES DERIVED FROM MESENCHYMAL STROMAL CELLS, PRODUCTION METHOD AND USE OF THE CONCENTRATE | OMICS BIOTECNOLOGIA ANIMAL LTDA. (BR) | 2024-02-22 | — | — | WO | claimed |
| CN-115711995-A | Use of gastric cancer-associated urinary protein markers for diagnosis or monitoring of gastric cancer treatment | 中国人民解放军空军军医大学 | 2023-02-24 | — | — | CN | claimed |
| US-20220196524-A1 | PROCESS FOR PREPARING A PEPTIDE SAMPLE | SPOT TO LAB (FR) | 2022-06-23 | — | — | US | claimed |
| EP-3994704-A1 | METHOD AND SYSTEM FOR PERSONALIZED, MOLECULAR BASED HEALTH MANAGEMENT AND DIGITAL CONSULTATION AND TREATMENT | Molecular You Corporation (CA) | 2022-05-11 | — | — | EP | claimed |
| EP-3973296-A1 | METHOD FOR PREPARING A PEPTIDE SAMPLE | Centre Hospitalier Universitaire de Montpellier (FR) | 2022-03-30 | — | — | EP | claimed |
| CN-121499821-B | Application of product of targeting Vasorin protein in preparation of products for diagnosing or treating sugar tolerance-reduced nephropathy | 天津医科大学朱宪彝纪念医院(天津医科大学代谢病医院、天津代谢病防治中心) | 2026-05-15 | — | — | CN | disclosed |
| CN-121499821-B | Application of product of targeting Vasorin protein in preparation of products for diagnosing or treating sugar tolerance-reduced nephropathy | 天津医科大学朱宪彝纪念医院(天津医科大学代谢病医院、天津代谢病防治中心) | 2026-05-15 | — | — | CN | disclosed |
| CN-121499821-B | Application of product of targeting Vasorin protein in preparation of products for diagnosing or treating sugar tolerance-reduced nephropathy | 天津医科大学朱宪彝纪念医院(天津医科大学代谢病医院、天津代谢病防治中心) | 2026-05-15 | — | — | CN | disclosed |
| US-12618060-B2 | Nucleic acid molecules | CureVac SE (DE) | 2026-05-05 | — | — | US | disclosed |
| US-20260091025-A1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | ELECTROPHORETICS LIMITED (GB) | 2026-04-02 | — | — | US | disclosed |
| US-20220093269-A1 | INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM | LABRADOR DIAGNOSTICS LLC (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220073944-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
| CN-111796043-B | Papaverine hydrochloride powder injection for injection and quality detection method thereof | 山东北大高科华泰制药有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-111789818-B | Papaverine hydrochloride pharmaceutical composition for injection and preparation method thereof | 山东北大高科华泰制药有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-20220023347-A9 | PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618060-B2 | Nucleic acid molecules | TP53, MICA, TAP1 | GLA 3160/4885PDE3A 3784/4885PDE3B 4189/4885 |
| US-20260091025-A1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | PYGB, PACSIN2, PPP3CA | GLA 724/4885PDE3A 444/4885PDE3B 625/4885 |
| US-20220073944-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | NSUN3, TRDMT1, NSUN2 | GLA 2245/4885PDE3A 4624/4885PDE3B 4665/4885 |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | HDLBP, LIPG, ABCB4 | GLA 1324/4885PDE3A 4294/4885PDE3B 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.